Fidelis Capital Partners’s Biogen BIIB Stock Holding History

Fidelis Capital Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,703	Closed	-$239K	–	495
2025 Q3	$239K	Buy	+1,703	New	+$230K	0.02%	424

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelis Capital Partners's BIIB Position: Q4 2025 in Review

Fidelis Capital Partners sold out of Biogen (BIIB) in Q4 2025, closing a stake of 1,703 shares — an estimated $239K sold.

Fidelis Capital Partners first reported a position in BIIB in Q3 2025 and held it in 1 quarter. The position peaked at $239K in Q3 2025. 1,000 funds tracked by Wall St. Rank hold BIIB as of Q4 2025.

Fidelis Capital Partners reported no remaining Biogen position as of Q4 2025 after selling out during the quarter.
Fidelis Capital Partners sold 1,703 Biogen shares in Q4 2025, an estimated $239K.
Fidelis Capital Partners first reported a position in Biogen in Q3 2025 and held it in 1 quarter.
Fidelis Capital Partners's Biogen position peaked at $239K in Q3 2025.
1,000 funds tracked by Wall St. Rank held Biogen as of Q4 2025.

Based on Fidelis Capital Partners's 13F filing for Q4 2025, filed 9 Feb 2026.